Incyte (INCY) Tops Q4 EPS by 20c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
Incyte (INCY): Tumor Removal Drives Estimate Cut - UBS
February 12, 2016 8:57 AM ESTUBS analyst, Matthew Roden, looked through a good quarter for Incyte (NASDAQ: INCY) to the importance of pipeline growth. He adjusted his model to remove the contribution of Jakafi in solid tumors which led him to cut his PT to $88 from $110. No change to the Buy rating though as the new PT implies 35% upside.
Although 4Q operations beat cleanly on the top/bottom lines, 2016 opex guidance and in particular the failure of Jakafi in solid tumors caused a PT cut to $88 (from $110) as solid tumors (and '110) are removed from the model. Risk-adjusted... More
Incyte (INCY) to Halt Ruxolitinib + Capecitabine Phase 3 in Advanced or Metastatic Pancreatic Cancer
February 11, 2016 6:46 AM ESTIncyte Corporation (Nasdaq: INCY) announced its decision to discontinue the Phase 3 study (JANUS 1) of ruxolitinib or placebo in combination with capecitabine for the second-line treatment of patients with advanced or metastatic pancreatic cancer. The decision to stop the study was made after a planned interim analysis of JANUS 1 demonstrated that ruxolitinib plus capecitabine did not show a sufficient level of efficacy to warrant continuation.
Following these results, and the... More
